CLINICAL TRIAL SUMMARY

MDACC Study No:2010-0295 (clinicaltrials.gov NCT No: NCT01101594)
Title:A Phase I/II Study of hLL-1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients with Multiple Myeloma
Principal Investigator:Sheeba K. Thomas
Treatment Agent:hLL1-DOX
Study Status:Terminated
Study Description:The goal of Phase 1 of this clinical research study is to find the highest
tolerable dose of hLL1-DOX when given to patients with MM.

The goal of Phase 2 of this study is to learn if hLL1-DOX can help to control
MM.

The safety of this drug will be studied in both phases.

Hide details for General InformationGeneral Information

Disease Group:Myeloma
Phase of Study:Phase I/Phase II
Treatment Agents:hLL1-DOX
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Immunomedics
Return Visit:
Home Care:


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Sheeba K. Thomas
Dept:Lymphoma/Myeloma
For Clinical Trial Enrollment:713-792-2860
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults